FDA Releases Q&A on ANDAs and Stability Testing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Releases Q&A on ANDAs and Stability Testing


FDA has released answers to questions received during the public comment period for the draft guidance document Stability Testing of Drug Substances and Products, Questions and Answers, published in the Federal Register on September 25, 2012 as well as responses to comments received on the draft of this guidance published in the Federal Register on August 27, 2013. The Q&A document responds to concerns regarding drug master files (DMFs), drug product manufacturing and packaging, and stability studies.

In the Q&A document, FDA clarifies the stability testing data recommendations for abbreviated new drug applications (ANDAs). According to the Q&A document, “the stability guidance covers all new ANDAs under the Federal Food, Drug, and Cosmetic Act, section 505 (j), and DMFs (Type II for drug substances that support the ANDAs). It does not apply to postapproval changes.”

FDA addresses questions related to the timing and amount of accelerated stability and long-term stability data required for an ANDA, intermediate stability study requirements, stability bracketing and matrixing, shelf-life calculation requirements, sample storage times, and more.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here